Psychiatry research · 2026
Virtual reality-based Avatar Therapy for treatment-resistant major depressive disorder: A pilot study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Giguère Sabrina, Potvin Stéphane, Fortier Alexandra, Phraxayavong Kingsada, Lespérance François, Do André, Bahremand Arash, Dumais Alexandre
Аннотация
BACKGROUND: Major depressive disorder (MDD) is a common and disabling mental health condition, with a substantial proportion of patients failing to achieve symptom relief through standard pharmacological or psychotherapeutic treatments. Treatment-resistant depression (TRD), therefore, remains a significant clinical and public health challenge. To address this, our team developed Avatar Therapy, a virtual reality-based intervention with strong experiential and relational components. This pilot clinical trial aimed to evaluate the short-term efficacy of Avatar Therapy for TRD on 12 participants.
METHODS: During therapy sessions, participants engaged in dialogue in virtual reality with an avatar representing a person who played a significant role in their depressive symptoms. The avatar was animated in real-time by the therapist. The primary outcomes were the rates of response and remission, along with depressive symptom severity. Secondary outcomes were severity of anxiety symptoms, self-esteem, quality of life, and functioning. Changes in these outcomes between the pre- and post-therapy assessment periods were analyzed using linear mixed-effects models.
RESULTS: Among completers, the response rate was 80%, and the remission rate was 20%. At post-therapy, results showed a significant large reduction in depressive symptoms as measured both by self-report (d=1.48, p<0.001) and clinician-rated assessments (d=1.36, p<0.001). Moreover, large significant improvements were observed in the severity of anxiety (d=1.27, p<0.001), self-esteem (d=1.11, p=0.003), quality of life (d=1.42, p<0.001), and functioning (d=1.21, p=0.003).
CONCLUSION: This unique psychotherapy shows promising preliminary results for treating individuals with TRD. Future trials should assess efficacity in larger controlled samples and its long-term out.
METHODS: During therapy sessions, participants engaged in dialogue in virtual reality with an avatar representing a person who played a significant role in their depressive symptoms. The avatar was animated in real-time by the therapist. The primary outcomes were the rates of response and remission, along with depressive symptom severity. Secondary outcomes were severity of anxiety symptoms, self-esteem, quality of life, and functioning. Changes in these outcomes between the pre- and post-therapy assessment periods were analyzed using linear mixed-effects models.
RESULTS: Among completers, the response rate was 80%, and the remission rate was 20%. At post-therapy, results showed a significant large reduction in depressive symptoms as measured both by self-report (d=1.48, p<0.001) and clinician-rated assessments (d=1.36, p<0.001). Moreover, large significant improvements were observed in the severity of anxiety (d=1.27, p<0.001), self-esteem (d=1.11, p=0.003), quality of life (d=1.42, p<0.001), and functioning (d=1.21, p=0.003).
CONCLUSION: This unique psychotherapy shows promising preliminary results for treating individuals with TRD. Future trials should assess efficacity in larger controlled samples and its long-term out.